151 results
8-K
EX-99.1
JAGX
Jaguar Health Inc
23 May 24
Jaguar Health, Inc. Announces Reverse Stock Split
6:20am
such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing
424B5
JAGX
Jaguar Health Inc
23 May 24
Prospectus supplement for primary offering
6:05am
”)-which includes symptoms such as chronic and/or episodic debilitating diarrhea (loose and/or watery stools), urgency, bowel incontinence and abdominal … for chronic idiopathic/functional diarrhea. Crofelemer powder for oral solution is being developed to support orphan or rare disease indications for adults
424B3
2sdtksp smyqx
1 May 24
Prospectus supplement
5:22pm
8-K
EX-99.1
qevd5q75kr bv8l
9 Apr 24
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
5:26pm
8-K
EX-99.1
mgl91
21 Mar 24
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory
4:30pm
8-K
EX-99.1
k7c4xghnrly5uqxab
8 Nov 23
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq’s Bid Price Rule
5:03pm
8-K
EX-99.1
xiks2mpl09n5ufbp6bht
14 Aug 23
Jaguar Health Reports Second Quarter 2023 Financial Results
9:05am
8-K
EX-99.1
f32si460
7 Jul 23
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
5:27pm
8-K
dsvqb2ln
3 Jul 23
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-99.1
ie9cz6vt
19 May 23
Departure of Directors or Certain Officers
5:00pm